Results:11 pts have been treated to date; 3 in Group 1, and 8 in Group 2. All pts have received at least 2 cycles of the combination treatment; 2 pts completed 8 cycles, and 2 pts remain on study. Tumour types include lung, prostate, gastric, pancreatic, nasopharyngeal and metastatic squamous carcinoma.
Early signals of tumour response based on RECIST 1.1 criteria include
stable disease in 2 pts (SD at 8 weeks and at 16 weeks);
partial response (PR) in 1 patient at 16 weeks;
complete response (CR) in 2 pts, both with ongoing CR at 24 weeks.
Five pts had disease progression, and
1 pt was withdrawn due to suspected immune mediated myositis and hepatitis resulting from nivolumab and was not evaluable.
Ann: IONIC Trial Abstract Published at ASCO, page-18
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $30.68M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 10.5¢ | $15.23K | 145.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7857 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.5¢ | 50000 | 1 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| NOX (ASX) Chart |